Treeline's BCL6 degrader TLN-121 posts 84% response rate in lymphoma
Early Phase 1 monotherapy data show a 32% complete response rate and no dose-limiting toxicities in 19 heavily pretreated lymphoma patients, ahead of expanded cohorts testing durability.
Executive Summary
- Treeline's oral BCL6 degrader produced responses in most of a small group of heavily pretreated lymphoma patients in a Phase 1 dose-escalation trial, with almost a third achieving complete responses and no dose-limiting toxicities reported.
- The trial's registered primary endpoints are safety and pharmacokinetic measures, not tumor response, so the response-rate figures are secondary findings from an early, small, open-label cohort rather than a confirmed primary outcome.
- Responses occurred in patients who had already failed multiple prior treatment lines, including a share who had received T-cell engagers or CAR-T therapy, indicating activity persists after those modalities stop working.
- The disclosure arrived inside a merger registration filing tied to Treeline's combination with Standard BioTools, and the trial itself remains in early dose escalation with expansion cohorts and 2027 follow-up data still ahead.
The data
Treeline Biosciences, Inc. reported that TLN-121, an oral protein degrader targeting BCL6, produced an overall response rate of 84% (16 of 19 evaluable patients) and a complete response rate of 32% (6 of 19), by Lugano criteria, as of a March 6, 2026 data cutoff. The results came from the dose-escalation portion of an ongoing Phase 1 trial, NCT07082803, enrolling patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, or T-follicular helper peripheral T-cell lymphoma. Complete responses occurred across all three histologies, and patients had received 2 to 8 prior lines of therapy, with half of the DLBCL and follicular lymphoma patients having already received a T- or immune-cell engager and a third having received prior CAR-T therapy. "The initial clinical data for TLN-121 bode very well for its potential to play a broad role in the management of lymphoma," said Josh Bilenker, M.D., co-founder and chief executive officer of Treeline. Standard+1Standard BioTools Announces Filing of Registration Statement in Connection with Treeline ...Jul 20, 2026TLN-121 in Relapsed or Refractory Non-Hodgkin LymphomasNCT07082803
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial was built to test
The registered primary endpoints for NCT07082803 are safety measures: clinically significant QT interval changes, laboratory abnormalities, incidence of treatment-emergent and treatment-related adverse events, and dose-limiting toxicities following TLN-121 alone or combined with TLN-254. Tumor response, measured by complete response rate, duration of response, and objective response rate under Lugano criteria, is registered as a secondary endpoint. TLN-121 was reported as well tolerated, with no dose-limiting toxicities and most treatment-emergent and treatment-related adverse events graded 1. That safety read is what the trial's primary endpoint structure was designed to answer; the response-rate figures are an early secondary signal layered on top of it. NCT07082803+1TLN-121 in Relapsed or Refractory Non-Hodgkin LymphomasNCT07082803Standard BioTools Announces Filing of Registration Statement in Connection with Treeline ...Jul 20, 2026
The design and its limits
The trial is open-label and non-randomized, targeting 180 total participants, with a primary completion date of September 1, 2030. The 19-patient efficacy-evaluable group behind the reported response rates is a fraction of that target, drawn from the dose-escalation portion before Treeline's planned expansion cohorts, which will test TLN-121 both as monotherapy and combined with other anti-lymphoma agents. Enrollment has tracked at its anticipated level with no jump flagged against the trial's target, and the registry shows no endpoint amendments or primary-completion-date changes since the study was added in July 2025. The disclosure itself arrived inside a Form S-4 registration statement tied to Treeline's merger with Standard BioTools Inc., rather than a standalone clinical data release. NCT07082803+1TLN-121 in Relapsed or Refractory Non-Hodgkin LymphomasNCT07082803Standard BioTools Announces Filing of Registration Statement in Connection with Treeline ...Jul 20, 2026
The competitive setting
BCL6 is not currently characterized as TLN-121's confirmed lead target in available records, so no isolation or first-in-class claim attaches to this readout. The broader relapsed or refractory non-Hodgkin lymphoma field includes agents built on different mechanisms already in later-stage testing, among them Genmab's CD20-directed bispecific epcoritamab in Phase 3 follicular lymphoma trials and AstraZeneca's CD19-directed bispecific AZD0486 also in Phase 3 follicular lymphoma testing. Those programs target different antigens through different modalities than TLN-121's protein-degradation approach, so they inform the competitive backdrop for relapsed or refractory lymphoma rather than serving as direct mechanistic comparators. Given how heavily pretreated the responding patients were, including prior T-cell engager and CAR-T exposure, the result that would extend this signal is durable response as expansion cohorts enroll larger numbers and longer follow-up matures.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.